Physician profile
Duane Johnson
NPI 1750392676
$2,134.63
in general payments reported to CMS, 2019-2025
19 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.78 · 2022: $130 · 2024: $667 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,991.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $447.57 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $382.46 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Axsome Therapeutics, INC. | $207.90 | 2024-2025 | Auvelity, Symbravo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $173.88 | 2024-2025 | Caplyta |
| Corium, LLC | $146.06 | 2024-2025 | Azstarys |
| Pfizer INC. | $136.57 | 2025 | |
| Novo Nordisk INC | $122.03 | 2022-2025 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $96.74 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $95.64 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $62.53 | 2024-2025 | Gemtesa |
| Lilly USA, LLC | $56.77 | 2022-2025 | Zepbound, Mounjaro |
| Dexcom, INC. | $42.29 | 2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $34.21 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.36 | 2024-2025 | Xifaxan |
| Shield Therapeutics INC | $23.21 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $21.50 | 2025 | |
| Amgen INC. | $20.83 | 2024 | Repatha, Otezla |
| Boston Scientific Corporation | $16.90 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.18 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duane Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.